Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

Inclusion Criteria:

* Signed Informed consent.
* Initial histopathologic diagnosis of epithelial ovarian cancer, cancer of the fallopian tube or primary peritoneal carcinoma
* Women ≥ 18 years
* ECOG performance status ≤ 1 (Eastern Cooperative Oncology Groupperformance)
* Initial surgical cytoreduction as primary treatment combinated with Platinum- based chemotherapy administered as part of primary therapy.

Failure of the primary treatment as manifested by recurrent disease that have achieved a second or third complete response with a second or third-line chemotherapy (platinum-based or not).

The complete response to the second or third-line chemotherapy is defined as non symptoms of cancer persistence, normal CA-125 (cancer antigen 125), negative medical examination, and no evidence of disease in a TAC.

* At least 4 cycles of second or third-line chemotherapy must have been administered
* Surgery performed at first or second relapse in conjunction with second or third-line chemotherapy is permitted.

Exclusion Criteria:

* Acute or chronic infection
* Concomitant treatment with cancer chemo- and/or radiotherapy
* Exposure to an investigational product within 28 days of first infusion
* Previous treatment with murine monoclonal antibodies
* Inadequate renal function: creatinine \>1.5 upper limit of normal \[ULN\] and/ or calculated creatinine clearance ≥ 50 mL/min
* Inadequate hepatic function (AST, ALT, \>2.5 xULN; bilirubin \>1.5 xULN), Hypoalbuminaemia \< 3 g/dL
* Platelets \<80000 cells/mm3; absolute neutrophil count (ANC) \<1000 cells/mm3,
* Hb \< 8g/dL and PTT \> 2 x ULN
* Patients with occlusive intestinal or symptomatic sub-occlusive intestinal within the last 30 days.
* Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia
* Unable or unwilling to comply fully with the protocol.
* Any co-morbid disease that would increase risk of toxicity according to investigator judgment
* Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures
* Exposure to investigational product, cancer, chemo-or radiotherapy within the last 28 days (6 weeks for nitrosoureas or mitomycin C) before first infusion
* Known or suspected hypersensitivity to catumaxomab or similar antibodies
* Long-lasting steroid treatment (≥ 7 days), Patients should only be included after stepwise discontinuation and free of steroids for a minimum of 5 days